OBJECTIVE: To examine the relationship between changes in anti-double-stranded DNA (anti-dsDNA) antibody levels and the risk of renal flare in patients with systemic lupus erythematosus (SLE), using data from 2 randomized, controlled trials. METHODS: Analyses were based on 487 patients with SLE and a history of lupus nephritis who had an anti-dsDNA antibody titer >/=15 IU/ml at baseline, as measured by Farr assay. Results are presented for the combined population of patients, the placebo arms, and the drug treatment arms in which a dsDNA-based bioconjugate (abetimus sodium; LJP 394) was used. RESULTS:Changes in anti-dsDNA antibody levels were inversely correlated with changes in the C3 level (P < 0.0001 in both trials). Cox proportional hazards regression models showed that changes in anti-dsDNA antibody levels correlated with the risk of renal flare. The models predicted that a point estimate of a 50% reduction in anti-dsDNA antibody levels is associated with a 52% reduction (95% confidence interval [95% CI] 26-68%, nominal P = 0.0007) and a 53% reduction (95% CI 33-69%, nominal P < 0.0001) in the risk of renal flare in the 2 trials, respectively. In the 2 trials, the incidence of renal flare was lower in patients with sustained reductions in anti-dsDNA antibodies (3.0% and 4.1%, respectively) than in patients with stable or increasing antibody levels (21.3% and 20.3%, respectively). CONCLUSION:Changes in anti-dsDNA antibody levels were directly correlated with the risk of renal flare and inversely correlated with changes in the C3 level. Reducing anti-dsDNA antibody levels may represent a therapeutic objective in SLE patients with lupus nephritis, because it is associated with a reduced risk of renal flare.
RCT Entities:
OBJECTIVE: To examine the relationship between changes in anti-double-stranded DNA (anti-dsDNA) antibody levels and the risk of renal flare in patients with systemic lupus erythematosus (SLE), using data from 2 randomized, controlled trials. METHODS: Analyses were based on 487 patients with SLE and a history of lupus nephritis who had an anti-dsDNA antibody titer >/=15 IU/ml at baseline, as measured by Farr assay. Results are presented for the combined population of patients, the placebo arms, and the drug treatment arms in which a dsDNA-based bioconjugate (abetimus sodium; LJP 394) was used. RESULTS: Changes in anti-dsDNA antibody levels were inversely correlated with changes in the C3 level (P < 0.0001 in both trials). Cox proportional hazards regression models showed that changes in anti-dsDNA antibody levels correlated with the risk of renal flare. The models predicted that a point estimate of a 50% reduction in anti-dsDNA antibody levels is associated with a 52% reduction (95% confidence interval [95% CI] 26-68%, nominal P = 0.0007) and a 53% reduction (95% CI 33-69%, nominal P < 0.0001) in the risk of renal flare in the 2 trials, respectively. In the 2 trials, the incidence of renal flare was lower in patients with sustained reductions in anti-dsDNA antibodies (3.0% and 4.1%, respectively) than in patients with stable or increasing antibody levels (21.3% and 20.3%, respectively). CONCLUSION: Changes in anti-dsDNA antibody levels were directly correlated with the risk of renal flare and inversely correlated with changes in the C3 level. Reducing anti-dsDNA antibody levels may represent a therapeutic objective in SLEpatients with lupus nephritis, because it is associated with a reduced risk of renal flare.
Authors: Jill P Buyon; Mimi Y Kim; Marta M Guerra; Sifan Lu; Emily Reeves; Michelle Petri; Carl A Laskin; Michael D Lockshin; Lisa R Sammaritano; D Ware Branch; T Flint Porter; Allen Sawitzke; Joan T Merrill; Mary D Stephenson; Elisabeth Cohn; Jane E Salmon Journal: Clin J Am Soc Nephrol Date: 2017-04-11 Impact factor: 8.237
Authors: Sung Soo Ahn; Seung Min Jung; Juyoung Yoo; Sang-Won Lee; Jason Jungsik Song; Yong-Beom Park Journal: Rheumatol Int Date: 2019-09-24 Impact factor: 2.631
Authors: Sonya VanPatten; Shan Sun; Mingzhu He; Kai Fan Cheng; Ahmad Altiti; Angelos Papatheodorou; Czeslawa Kowal; Venkatesh Jeganathan; James M Crawford; Ona Bloom; Bruce T Volpe; Christian Grant; Nathalie Meurice; Thomas R Coleman; Betty Diamond; Yousef Al-Abed Journal: J Med Chem Date: 2016-09-20 Impact factor: 7.446
Authors: Stephen W Olson; Jessica J Lee; Lisa K Prince; Thomas P Baker; Patricia Papadopoulos; Jess Edison; Kevin C Abbott Journal: Clin J Am Soc Nephrol Date: 2013-07-05 Impact factor: 8.237
Authors: Ramon G Bonegio; Jessica D Lin; Britte Beaudette-Zlatanova; Michael R York; Hanni Menn-Josephy; Kei Yasuda Journal: J Immunol Date: 2019-01-04 Impact factor: 5.422